The US Food and Drug Administration (FDA) recently approved a drug created by Eli Lilly that aims to address the early symptoms of Alzheimer’s disease. This medication, known as Kisunla, is intended for use by individuals with mild cognitive impairment or in the mild dementia stage of the disease.
The FDA highlighted that patients treated with Kisunla exhibited a statistically significant reduction in clinical decline, as well as meeting several other criteria. This approval places Kisunla alongside a limited number of other drugs sanctioned by the US regulator for treating Alzheimer’s, a disease that impacts over 6.5 million Americans.
Anne White, executive vice president of Eli Lilly, expressed great satisfaction with Kisunla’s performance in treating early symptomatic Alzheimer’s disease. She emphasized the importance of early detection and diagnosis in maximizing the benefits of such medications.
The Alzheimer’s Association, a non-profit organization dedicated to combating the disease, hailed the FDA’s decision as a significant step forward. The president of the association, Joanne Pike, emphasized the value of having multiple treatment options available and the impact this approval would have on individuals and families affected by Alzheimer’s.
In Alzheimer’s disease, tangles and plaques made up of tau and amyloid beta proteins accumulate in the brain, causing the death of brain cells and subsequent brain shrinkage. The approval of Kisunla represents hope for individuals with early symptoms of Alzheimer’s to slow down the progression of the disease and improve their quality of life.
This news of the FDA’s approval of Kisunla offers a glimmer of hope for those impacted by Alzheimer’s disease, providing new treatment options and the potential for increased quality of life for those in the early stages of the illness.
Leave a Reply